Biogen logo

Biogen (BIIB) Q1 2026 Earnings

BIIB·Reported April 29, 2026·Before market open

Biogen reported Q1 2026 revenue of $2.5B (+1.9% YoY), beat analyst consensus of $2.3B by $191.0M. Diluted EPS came in at $3.57 (+18.2% YoY), beat the $3.05 consensus by $0.52. Biogen reports across 4 business segments, led by Neurology, Rare Disease, and Anti-CD20 Therapeutic Programs.

Revenue
$2.5Bbeat by $191.0M
Consensus: $2.3B
Diluted EPS
$3.57beat by $0.52
Consensus: $3.05
SEC

SEC Filings

Earnings release8-K · 0000875045-26-000042
Quarterly report10-Q · 0000875045-26-000045

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Biogen's Q1 2026 earnings report.

Biogen (BIIB) reported Q1 2026 earnings on April 29, 2026 before market open.

Biogen reported revenue of $2.5B and diluted EPS of $3.57 for Q1 2026.

Revenue beat the consensus estimate of $2.3B by $191.0M. EPS beat the consensus estimate of $3.05 by $0.52.

Compared to the same quarter a year prior, revenue grew 1.9% from $2.4B a year earlier and diluted EPS grew 18.2% from $3.02.

You can read the 8-K earnings release (0000875045-26-000042) and the 10-Q periodic report (0000875045-26-000045) directly on SEC EDGAR. The filing index links above go to sec.gov.